Author Archives: Iqra Mumal MSc

2 CF Case Reports Show Successful Use of GM-CSF for Treating Nontuberculous Mycobacteria

Savara Pharmaceuticals announced the publication of two case reports demonstrating that inhaled granulocyte-macrophage colony stimulating factor (GM-CSF) either eradicated or dramatically reduced Mycobacterium abscessus (M. abscessus) infection, improved clinical outcomes, and was well-tolerated in patients with cystic fibrosis (CF). The results were published in the European Respiratory Journal in an…

Humanigen’s Inflammation Therapy Is Only Modestly Effective in CF Patients with an Infection, Trial Shows

Humanigen’s anti-inflammatory therapy KB001-A is safe but only modestly effective in cystic fibrosis patients with a Pseudomonas aeruginosa bacteria infection, a Phase 2 clinical trial indicates. In addition to displaying limited ability to decrease markers of patients’ lung inflammation, it failed to generate substantial decreases in their bacteria levels or improvements in their…

#NACFC2017 – Two Phase 3 Studies of Tezacaftor/Ivacaftor Combo Show Positive Results in CF Patients

Vertex Pharmaceuticals, a clinical-stage biopharmaceutical company, recently announced that two Phase 3 studies evaluating its tezacaftor/ivacaftor combination therapy have shown statistically significant and clinically meaningful improvements in lung function in patients with certain mutations associated with cystic fibrosis (CF). The first study, called EVOLVE (NCT02347657), was conducted to…

Exotect Grant to Target New Therapies for Airway Mucous Secretion in CF, Other Diseases

The National Institutes of Health (NIH) has awarded Exotect a $224,576 Small Business Technology Transfer grant to develop small molecule therapies to treat cystic fibrosis and other diseases characterized by excessive airway mucous secretion. These include chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD) and asthma. Exotect, a preclinical early-stage Fannin Innovation…

Dual Contrast Agents May Allow for More Precise and Color-coded MRI Scans

Magnetic resonance imaging (MRI) scans, already important to both doctors treating patients and researchers conducting trials, might soon distinguish diseased and healthy tissue in differing colors, improving efforts to map and potentially diagnose and monitor diseases such as cystic fibrosis. A method allowing for two contrasting agents to be visible on MRI scans, called Dual…


Featured Column

Words Between Worlds: Improving Cross-class Communication in Medical Spaces

A banner for Kate Delany's "Breathe and Believe" column that depicts a pair of lungs with flowers blossoming from them.
Columnist Kate Delany investigates how communication between patients, family members, and doctors is often shaped by class origins.

Read the Column


Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.